In vitro pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of Trichophyton tonsurans from tinea capitis patients

References

• Chan YC, Friedlander SF. Therapeutic options in the treatment of tinea capitis. Expert Opin Pharmacother 2004; 5: 219–227.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Summerbell RC. Tinea capitis. Med Mycol 2000; 38: 255–287.
   PubMed Web of Science ®Google Scholar
• Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann 2005; 34: 191–200.
   PubMed Web of Science ®Google Scholar
• Fuller LC, Smith CH, Cerio R, . A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001; 144: 321–327.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Adam P, Dlova N, . Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 2001; 18: 433–438.
   PubMed Web of Science ®Google Scholar
• Haroon TS, Hussain I, Aman S, . A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996; 135: 86–88.
   PubMedGoogle Scholar
• Lipozencic J, Skerlev M, Orofino-Costa R, . A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 2002; 146: 816–823.
   PubMed Web of Science ®Google Scholar
• Lopez-Gomez S, Del Palacio A, Van Cutsem J, . Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994; 33: 743–747.
   PubMedGoogle Scholar
• Howard DH. Pathogenic Fungi in Humans and Animals.
   Google Scholar
• Straughn AB, Meyer MC, Raghow G, Rotenberg K. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J Pharmacokinet Biopharm 1980; 8: 347–362.
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne PA, 2002.
   Google Scholar
• Singh J, Zaman M, Gupta AK. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol 2007; 45: 595–602.
   PubMed Web of Science ®Google Scholar
• Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics 2004; 114: 1312–1315.
   PubMed Web of Science ®Google Scholar
• Silverberg NB, Weinberg JM, DeLeo VA. Tinea capitis: focus on African American women. J Am Acad Dermatol 2002; 46: S120–S124.
   Google Scholar
• Williams JV, Eichenfield LF, Burke BL, Barnes-Eley M, Friedlander SF. Prevalence of scalp scaling in prepubertal children. Pediatrics 2005; 115: e1–e6.
   PubMedGoogle Scholar
• Mohrenschlager M, Korting HC, Seidl HP, Ring J, Abeck D. Tinea capitis. Therapeutic options in the post-griseofulvin era. Hautarzt 2002; 53: 788–794.
   PubMedGoogle Scholar
• Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341–344.
   PubMed Web of Science ®Google Scholar
• Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001; 39: 385–388.
   PubMed Web of Science ®Google Scholar
• Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003; 41: 4817–4819.
   PubMed Web of Science ®Google Scholar
• Chadeganipour M, Nilipour S, Havaei A. In vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan. Mycoses 2004; 47: 503–507.
   PubMedGoogle Scholar
• Ghannoum M, Isham N, Sheehan D. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial. J Clin Microbiol 2006; 44: 2579–80.
   PubMed Web of Science ®Google Scholar
• Osborne CS, Hofbauer B, Favre B, Ryder NS. In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine. Antimicrob Agents Chemother 2003; 47: 3634–3636.
   PubMedGoogle Scholar
• Manavathu EK, Vazquez JA, Chandrasekar PH. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 1999; 12: 213–219.
   PubMedGoogle Scholar
• Cross EW, Park S, Perlin DS. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 2000; 6: 155–161.
   PubMed Web of Science ®Google Scholar
• Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol 1972; 106: 344–348.
   PubMed Web of Science ®Google Scholar
• Shah VP, Riegelman S, Epstein WL. Determination of griseofulvin in skin, plasma, and sweat. J Pharm Sci 1972; 61: 634–636.
   PubMed Web of Science ®Google Scholar
• Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53: 1673–1678.
   PubMed Web of Science ®Google Scholar
• Sobue S, Sekiguchi K, Nabeshima T. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother 2004; 48: 216–223.
   PubMed Web of Science ®Google Scholar